Summary
A new drug called zorevunersen is helping children with a severe form of epilepsy called Dravet syndrome by reducing the number of seizures they experience. Early trial results show promising outcomes for children like eight-year-old Freddie Truelove in the UK. The drug is given through an injection into the spine and aims to fix a gene that affects the brain.
Key Facts
- Dravet syndrome affects approximately 1 in 15,000 babies and can cause many seizures a day.
- Zorevunersen is an experimental drug administered via spinal infusion to target a faulty gene in the brain.
- The drug has reduced the number of seizures from hundreds daily to just a few weekly for patients like Freddie Truelove.
- Clinical trial results, published in a medical journal, indicate the drug is safe for children aged two and older.
- The drug works by helping the brain produce more sodium channels needed for proper signaling.
- Early trials in the US and UK showed patients could have up to 90% fewer seizures on repeat doses.
- Continued research is necessary before the drug can become widely used.
- Experts are hopeful this drug will offer a better quality of life for children with Dravet syndrome and their families.
